DK2499238T3 - METHODS AND COMPOSITIONS FOR EXPANSION, IDENTIFICATION, CHARACTERIZATION, AND IMPROVEMENT OF THE STRENGTH OF GLYINIC DAMAGED PROGENITOR CELLS derived from mammals - Google Patents

METHODS AND COMPOSITIONS FOR EXPANSION, IDENTIFICATION, CHARACTERIZATION, AND IMPROVEMENT OF THE STRENGTH OF GLYINIC DAMAGED PROGENITOR CELLS derived from mammals Download PDF

Info

Publication number
DK2499238T3
DK2499238T3 DK10830580.6T DK10830580T DK2499238T3 DK 2499238 T3 DK2499238 T3 DK 2499238T3 DK 10830580 T DK10830580 T DK 10830580T DK 2499238 T3 DK2499238 T3 DK 2499238T3
Authority
DK
Denmark
Prior art keywords
cells
div
vitro
mammalian
grps
Prior art date
Application number
DK10830580.6T
Other languages
Danish (da)
English (en)
Inventor
Deborah A Eppstein
James T Campanelli
Robert Sandrock
Original Assignee
Q Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Q Therapeutics Inc filed Critical Q Therapeutics Inc
Application granted granted Critical
Publication of DK2499238T3 publication Critical patent/DK2499238T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
DK10830580.6T 2009-11-12 2010-11-09 METHODS AND COMPOSITIONS FOR EXPANSION, IDENTIFICATION, CHARACTERIZATION, AND IMPROVEMENT OF THE STRENGTH OF GLYINIC DAMAGED PROGENITOR CELLS derived from mammals DK2499238T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26044109P 2009-11-12 2009-11-12
US32679910P 2010-04-22 2010-04-22
PCT/US2010/055956 WO2011059952A1 (en) 2009-11-12 2010-11-09 Methods and compositions for expanding, identifying, characterizing and enhancing potency of mammalian-derived glial restricted progenitor cells

Publications (1)

Publication Number Publication Date
DK2499238T3 true DK2499238T3 (en) 2017-12-04

Family

ID=43991980

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10830580.6T DK2499238T3 (en) 2009-11-12 2010-11-09 METHODS AND COMPOSITIONS FOR EXPANSION, IDENTIFICATION, CHARACTERIZATION, AND IMPROVEMENT OF THE STRENGTH OF GLYINIC DAMAGED PROGENITOR CELLS derived from mammals

Country Status (11)

Country Link
US (2) US10351823B2 (https=)
EP (2) EP2499238B1 (https=)
JP (2) JP5952737B2 (https=)
CN (2) CN105602889A (https=)
AU (1) AU2010319680B2 (https=)
CA (1) CA2780541C (https=)
DK (1) DK2499238T3 (https=)
ES (1) ES2649396T3 (https=)
NO (1) NO2499238T3 (https=)
PL (1) PL2499238T3 (https=)
WO (1) WO2011059952A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003070171A2 (en) 2002-02-15 2003-08-28 Cornell Research Foundation, Inc. Myelination of congenitally dysmyelinated forebrains using oligodendrocyte progenitor cells
KR20110011658A (ko) 2008-05-08 2011-02-08 유니버시티 오브 로체스터 최적화된 세포 제제에 의한 수초 질환의 치료
JP6541577B2 (ja) 2013-02-06 2019-07-10 ユニバーシティー オブ ロチェスター ミエリン障害の治療のための誘導多能性細胞由来オリゴデンドロサイト前駆細胞
CA2959691A1 (en) * 2014-09-26 2016-03-31 The Procter & Gamble Company Products comprising malodor reduction materials
US9724432B2 (en) 2015-04-30 2017-08-08 University Of Rochester Non-human mammal model of human degenerative disorder, uses thereof, and method of treating human degenerative disorder
US11690876B2 (en) 2017-05-10 2023-07-04 University Of Rochester Methods of treating neuropsychiatric disorders
CN108624560B (zh) * 2018-06-01 2022-04-08 南京艾尔普再生医学科技有限公司 一种分化培养基及少突胶质前体细胞的制备方法
US10995325B2 (en) 2019-03-21 2021-05-04 Fornia Biosolutions, Inc. Additional phytase variants and methods
KR102322635B1 (ko) * 2021-06-11 2021-11-05 인제대학교 산학협력단 말초신경양 미세조직 제조방법 및 이의 용도
US20240254440A1 (en) * 2021-06-30 2024-08-01 The Regents Of The University Of California Methods to generate glial restricted neural progenitor cells and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235527B1 (en) * 1997-11-29 2001-05-22 University Of Utah Research Foundation Lineage restricted glial precursors from the central nervous system
CA2295197A1 (en) 1999-09-08 2001-03-08 Appleton Papers Inc. Thermally-responsive record material
US6878543B1 (en) * 1999-10-25 2005-04-12 Nsgene Sa Cultures of GFAP+ nestin+ cells that differentiate to neurons
AR046076A1 (es) * 2003-07-18 2005-11-23 Otsuka Pharma Co Ltd Procedimiento para obtener una poblacion homogenea de celulas precursoras de oligodendrocitos y poblacion obtenida
US20050272149A1 (en) * 2004-06-02 2005-12-08 Life & Brain Gmbh Therapeutic delivery of adenosine into a tissue
US20090155223A1 (en) * 2007-08-14 2009-06-18 The Johns Hopkins University Cell-based compositions and methods for treating conditions of the nervous system

Also Published As

Publication number Publication date
CN102686721B (zh) 2016-02-10
JP6346629B2 (ja) 2018-06-20
EP2499238A1 (en) 2012-09-19
HK1174953A1 (zh) 2013-06-21
EP2499238B1 (en) 2017-08-30
JP2016146831A (ja) 2016-08-18
EP3269803A2 (en) 2018-01-17
AU2010319680B2 (en) 2014-05-29
NO2499238T3 (https=) 2018-01-27
CA2780541C (en) 2015-07-14
PL2499238T3 (pl) 2018-04-30
ES2649396T3 (es) 2018-01-11
EP3269803A3 (en) 2018-04-25
WO2011059952A1 (en) 2011-05-19
US20120230963A1 (en) 2012-09-13
CN105602889A (zh) 2016-05-25
CA2780541A1 (en) 2011-05-19
EP2499238A4 (en) 2013-10-02
US10351823B2 (en) 2019-07-16
CN102686721A (zh) 2012-09-19
JP2013510570A (ja) 2013-03-28
AU2010319680A1 (en) 2012-07-05
US20190032010A1 (en) 2019-01-31
JP5952737B2 (ja) 2016-07-13

Similar Documents

Publication Publication Date Title
DK2499238T3 (en) METHODS AND COMPOSITIONS FOR EXPANSION, IDENTIFICATION, CHARACTERIZATION, AND IMPROVEMENT OF THE STRENGTH OF GLYINIC DAMAGED PROGENITOR CELLS derived from mammals
US20250019653A1 (en) Induced pluripotent cell-derived oligodendrocyte progenitor cells for the treatment of myelin disorders
Wang et al. Human iPSC-derived oligodendrocyte progenitor cells can myelinate and rescue a mouse model of congenital hypomyelination
TWI586805B (zh) 獲得及維持在體外易於分化為寡樹突細胞－族系細胞之哺乳類神經幹細胞及／或神經祖源細胞的純或增富族群之培養方法
CN103396993B (zh) 衍生自灵长类胚胎干细胞的用于脊髓损伤的再髓鞘化和治疗的少突胶质细胞
Sandner et al. Neural stem cells for spinal cord repair
US20110014695A1 (en) Methods for obtaining adult human olfactory progenitor cells
KR20070109979A (ko) 신경퇴행성 증상의 치료를 위한 인간 신경 세포의 이식
Wang et al. Neurogenic potential of progenitor cells isolated from postmortem human Parkinsonian brains
CA2489206C (en) Method for producing neural cell
Kawaja et al. Technical strategies to isolate olfactory ensheathing cells for intraspinal implantation
US20120177612A1 (en) Methods for treating and/or reversing neurodegenerative diseases and/or disorders
EP3584312A1 (en) Neural cells expressing adenovirus e4orf1, and methods of making and using the same
HK1174953B (en) Methods and compositions for expanding, identifying, characterizing and enhancing potency of mammalian-derived glial restricted progenitor cells
Khanna et al. Generation and transplantation of dopaminergic neurons derived from embryonic stem cells
HK40045021A (en) Induced pluripotent cell-derived oligodendrocyte progenitor cells for the treatment of myelin disorders
HK40012172A (en) Neural cells expressing adenovirus e4orf1, and methods of making and using the same
Canzi Human stem cells for the treatment of motorneuron diseases: regenerative potential, translatability and development of new biotechnologies. Cellule staminali umane per la cura delle malattie degenerative del motoneurone
Mead Mesenchymal stem cell therapy for traumatic and degenerative eye disease
HK1093219B (en) Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury